Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

BMS and 2seventy bio announce positive results for multiple myeloma treatment

The results show that Abecma ‘significantly improves’ progression-free survival in relapsed and refractory multiple myeloma

- PMLiVE

Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

- PMLiVE

Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases

The Regulus programme is working to develop a next-generation JAK1 inhibitor for eosinophilic oesophagitis

- PMLiVE

JCVI publishes statement on London polio vaccination strategy

A total of 116 cases of the virus has been found in London’s wastewater since February

- PMLiVE

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer

- PMLiVE

My body. My choice. Are we all talking about the same thing?

By now you have all heard. In fact, the world has heard. The US Supreme Court has overturned Roe v Wade. The constitutional right to abortion in the US no...

- PMLiVE

BeiGene announces positive phase 3 trial results for liver cancer treatment

There were more than 900,000 new cases in 2020 of the most common type of primary liver cancer – unresectable hepatocellular carcinoma

- PMLiVE

Sanofi halts recruitment for trials assessing MS treatment

The pause in enrolment follows advice issued by the Independent Data Monitoring Committee

- PMLiVE

Michael J Fox Foundation awards Koneksa second research grant

The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease

- PMLiVE

FDA approves Bot Image’s AI software for the detection and diagnosis of prostate cancer

ProstateID combines artificial intelligence with traditional MRI scanning to significantly improve radiologic interpretation accuracy

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links